219 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
IONS Ionis Pharmaceuticals, Inc. $48.21 $6.62B N/A
Article Searches
IONS: BMO Capital Markets reits Outperform http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20170818135100 Aug 18, 2017 - BMO Capital Markets issues rating change for IONS
3 Stocks With Microsoft-Like Return Potential https://www.fool.com/investing/2017/08/22/3-stocks-with-microsoft-like-return-potential.aspx?source=iedfolrf0000001 Aug 22, 2017 - Microsoft is a legendary wealth builder. These three stocks are also poised to create plenty of millionaires in the future.
Ionis Pharmaceuticals' (IONS) CEO Stanley Crooke on Q2 2017 Results - Earnings Call Transcript https://seekingalpha.com/article/4096563-ionis-pharmaceuticals-ions-ceo-stanley-crooke-q2-2017-results-earnings-call-transcript?source=feed_all_articles Aug 08, 2017 - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2017 Earnings Conference Call August 08, 2017 11:30 AM ET Executives Stanley Crooke - Founder, Executive Chairman, CEO and President Wade Walke - VP of Cor
Ionis Pharmaceuticals (IONS) Misses on Q2 Earnings http://www.zacks.com/stock/news/271156/ionis-pharmaceuticals-ions-misses-on-q2-earnings?cid=CS-ZC--271156 Aug 08, 2017 - Ionis Pharmaceuticals' (IONS) reported loss of 9 cents including stock based compensation was wider than expectation. However, sales beat estimates.
Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs https://www.fool.com/investing/2017/08/11/ionis-pharmaceuticals-inc-growing-royalties-advanc.aspx?source=iedfolrf0000001 Aug 11, 2017 - A solid second quarter from the biotech, with growing royalties on Spinraza and two more drugs to be reviewed by regulators, and it regained full rights to two drugs after its partner declined to license them.
Why PTC Therapeutics, Inc. Dropped Today https://www.fool.com/investing/2017/10/03/why-ptc-therapeutics-inc-dropped-today.aspx?source=iedfolrf0000001 Oct 03, 2017 - Investors are unimpressed with data -- so far -- for the biotech's spinal muscular atrophy drug RG7916.
Here's Why Alnylam Pharmaceuticals Rallied 32.7% in September https://www.fool.com/investing/2017/10/05/heres-why-alnylam-pharmaceuticals-rallied-327-in-s.aspx?source=iedfolrf0000001 Oct 05, 2017 - Positive results from an important phase 3 clinical trial fueled optimism about the biotech.
Why Ionis Pharmaceuticals Inc. Slipped This Morning https://www.fool.com/investing/2017/10/24/why-ionis-pharmaceuticals-inc-slipped-this-morning.aspx?source=iedfolrf0000001 Oct 24, 2017 - Investors think it's awfully early for sales of this company's first blockbuster to stagnate.
Ionis Pharmaceuticals' Earnings Results Fuel Volatility https://www.fool.com/investing/2017/11/10/ionis-pharmaceuticals-q3-results-fail-to-spark-ral.aspx?source=iedfolrf0000001 Nov 10, 2017 - A confusing quarter and pipeline uncertainty have investors scratching their heads over what to do with this biotech stock.
Ionis Pharmaceuticals' (IONS) CEO Dr. Stan Crooke on Q3 2017 Results - Earnings Call Transcript https://seekingalpha.com/article/4123692-ionis-pharmaceuticals-ions-ceo-dr-stan-crooke-q3-2017-results-earnings-call-transcript?source=feed_sector_healthcare Nov 11, 2017 - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2017 Results Earnings Conference Call November 07, 2017 11:30 AM ET Executives Dr. Stan Crooke - Ionis' Chairman and CEO Lynne Parshall - COO Sarah Boyce -

Pages: 1234567891011...22

<<<Page 6>